Esperion Therapeutics Inc (ESPR) concluded trading on Wednesday at a closing price of $2.20, with 5.88 million shares of worth about $12.94 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.71% during that period and on January 22, 2025 the price saw a gain of about 2.33%. Currently the company’s common shares owned by public are about 195.44M shares, out of which, 195.08M shares are available for trading.
Stock saw a price change of -1.79% in past 5 days and over the past one month there was a price change of 1.85%. Year-to-date (YTD), ESPR shares are showing a performance of 0.00% which increased to 8.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.58 but also hit the highest price of $3.94 during that period. The average intraday trading volume for Esperion Therapeutics Inc shares is 6.10 million. The stock is currently trading -1.01% below its 20-day simple moving average (SMA20), while that difference is down -10.57% for SMA50 and it goes to -0.81% lower than SMA200.
Esperion Therapeutics Inc (NASDAQ: ESPR) currently have 195.44M outstanding shares and institutions hold larger chunk of about 65.92% of that.
The stock has a current market capitalization of $433.48M and its 3Y-monthly beta is at 1.02. It has posted earnings per share of -$0.66 in the same period. It has Quick Ratio of 1.37. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ESPR, volatility over the week remained 8.09% while standing at 6.47% over the month.
Analysts are in expectations that Esperion Therapeutics Inc (ESPR) stock would likely to be making an EPS of -0.13 in the current quarter, while forecast for next quarter EPS is 0 and it is -0.12 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.15 which is -0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 85.39% while it is estimated to increase by 95.38% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 18, 2024 offering a Neutral rating for the stock and assigned a target price of $4 to it. Coverage by Cantor Fitzgerald stated Esperion Therapeutics Inc (ESPR) stock as an Overweight in their note to investors on December 17, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from JP Morgan on November 20, 2023.
